News

“While it is important that we correct false assertions about how Lilly manages its data, it is even more important to set the record straight for patients who

The antibody was created using Abgenix’s proprietary XenoMouse technology and is the 11th antibody generated with Abgenix’s technology to move into the clinic phase. “We are pleased to

The agreement, previously announced by both companies on November 8, 2004, became effective after all conditions were satisfied, including expiration of the waiting period required under the Hart-Scott-Rodino

The trial was carried out in 1,349 healthy subjects aged 18 to 64, in 28 Canadian sites, between October 2003 and May 2004. Both one- and two-dose FluINsure

Results of the first study ever to assess efficacy across all symptoms commonly experienced during a migraine attack found that treatment with Zomig (zolmitriptan) nasal spray produced a

Pexeva is a branded selective serotonin reuptake inhibitor for the treatment of depression, obsessive/compulsive disorder, and/or panic disorder. Pexeva was launched by Synthon in February 2004, and is

Mylan’s vice chairman and CEO, Robert Coury, explained that King’s restating of its financial results for 2002, 2003 and the first half of 2004, violates the merger agreement.

The three compounds are BL-1030, a small molecule for the treatment of inflammatory bowel disease, BL-1050, a novel HIV therapeutic, and BL-2010, an innovative technology for the treatment

Under the agreement, Aceto will source the active pharmaceutical ingredients, manage the regulatory and quality control functions of production, and supply the final dosage form of the products